Trials / No Longer Available
No Longer AvailableNCT02389933
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCZ696 | immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration. |
Timeline
- First posted
- 2015-03-17
- Last updated
- 2021-02-15
Locations
286 sites across 18 countries: United States, Australia, Austria, Brazil, Croatia, Cyprus, France, Germany, Greece, Ireland, Lebanon, Malta, Panama, Philippines, Slovenia, Spain, Switzerland, United Arab Emirates
Source: ClinicalTrials.gov record NCT02389933. Inclusion in this directory is not an endorsement.